Business Insight 2008年出品

Table of Contents
The Pharmaceutical Market Outlook to 2018
Executive summary 12
Key challenges 12
Key opportunities 13
Analysis of the top 10 global pharma companies 14
Pfizer 15
GlaxoSmithKline 16
Merck and Co. 17
Roche 18
The future 19
Chapter 1 Key challenges 22
Summary 22
Introduction 23
Challenges facing R&D 24
Falling R&D productivity 24
Late stage pipeline attrition 27
Economic pressures 28
Regulatory hurdles 29
Competition from generics 33
Patent challenges 34
Biosimilars 35
Impact of challenges on pharma and its responses 37
Restructuring of R&D operations 37
Outsourcing sales 40
Mitigation strategies for genericization 41
Chapter 2 Key opportunities 44
Summary 44
iv
Introduction 45
Opportunities 45
Biotech still growing 45
New emerging markets 49
Asia 50
Demise of the blockbuster drug and emergence of the nichebuster 52
New technologies to boost niche drugs 55
Biomarkers 55
Theranostics 56
Drug repositioning 58
Chapter 3 Analysis of the top 10 global
pharma companies 62
Summary 62
Introduction 63
Top 10 companies 63
Product mix (small molecule/biologic) 68
Therapy area mix 69
Growth in oncology drugs 70
Geography of product sales 72
Asia 73
South America 74
R&D profiles 76
Growth strategies 79
Chapter 4 Pfizer 82
Summary 82
Introduction 83
Is bigger better? 83
Challenges 83
Patent expiration of Lipitor 83
Torcetrapib 84
Exubera 85
Strategy 85
New CEO 85
Job cuts and plant closures 86
New opportunities for global growth 86
Pipeline 86
Opportunities in emerging markets 87
v
Reducing costs where possible 88
Looking to Biotech 88
Mergers and acquisitions 89
Encysive Pharmaceuticals 89
Serenex 89
Coley Pharmaceutical 89
CovX 90
Pipeline 92
Sutent 95
Lyrica 96
Chapter 5 GlaxoSmithKline 98
Summary 98
Introduction 99
Challenges 99
Generic competition 99
Seretide/Advair 99
Avandia 100
Wellbutrin 100
Zofran 101
Imigran 101
Lack of therapy area diversification 101
Business Strategy 102
Financial Strategy 102
GSK’s new strategic priorities 103
Recently marketed products 104
Tykerb 104
Cervarix 105
Mergers and acquisitions 106
Sirtris Pharmaceuticals 106
Reliant Pharmaceuticals 107
Domantis Ltd 108
Pipeline 109
Bosatria (mepolizumab) 110
Ofatumumab 110
Zunrisa/Rezonic 110
Chapter 6 Merck & Co. 112
Summary 112
Introduction 113
Challenges 113
vi
Vioxx 113
Generic competition 114
Zocor 114
Fosamax 115
Cozaar/Hyzaar 115
Vaccines 115
Gardasil 116
Manufacturing problems 116
5 year strategy 117
Cost cutting measures 121
Boosting revenue 121
Utilizing emerging markets 121
Licensing 122
Mergers and acquisitions 123
NovaCardia 123
Sirna Therapeutics 123
Abmaxis 124
GlycoFi 124
Pipeline 125
telcagepant 125
Cordaptive/Tredaptive 126
Chapter 7 Roche 130
Summary 130
Introduction 131
Challenges 131
The networked pharma model 131
Current strategy 133
Mergers and acquisitions 134
Arius Research 134
Mirus Bio Corporation 134
Piramed Limited 135
Alnylam Pharmaceuticals 135
Roche and Genentech 136
Pipeline 138
Ocrelizumab 138
Omnitarg 138
Chapter 8 The future 144
Summary 144
vii
Introduction 145
Future growth 145
Biotech partnerships and acquisitions 146
Pipeline 150
Personalized medicine 151
Predictive medicine 152
Pharmacogenomics 152
Molecular diagnostics 152
Biomarkers 153
Chapter 9 Appendix 156
Primary research methodology 156
Index 157

详细阐述回顾了2008年之前的世界医药市场,当前存在的挑战与机遇,重点介绍了世界前十大制药企业未来的策略.

[此贴子已经被作者于2009-1-12 16:05:20编辑过]